Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 7.7% in December

Adaptimmune Therapeutics plc (NASDAQ:ADAPGet Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 2,950,000 shares, an increase of 7.7% from the December 15th total of 2,740,000 shares. Currently, 2.0% of the company’s stock are short sold. Based on an average daily volume of 523,400 shares, the short-interest ratio is currently 5.6 days.

Insider Buying and Selling

In related news, CEO Adrian Rawcliffe sold 18,763 shares of the company’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $1.71, for a total transaction of $32,084.73. Following the completion of the sale, the chief executive officer now directly owns 24,882 shares of the company’s stock, valued at approximately $42,548.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 51,833 shares of company stock valued at $90,768. Company insiders own 17.37% of the company’s stock.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Hunter Associates Investment Management LLC raised its stake in Adaptimmune Therapeutics by 42.5% during the second quarter. Hunter Associates Investment Management LLC now owns 28,500 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 8,500 shares during the period. Key Client Fiduciary Advisors LLC raised its stake in Adaptimmune Therapeutics by 4.8% during the third quarter. Key Client Fiduciary Advisors LLC now owns 435,985 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 19,819 shares during the period. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 133.7% during the third quarter. Virtu Financial LLC now owns 40,503 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 23,175 shares during the period. State Street Corp raised its stake in Adaptimmune Therapeutics by 4.2% during the first quarter. State Street Corp now owns 640,620 shares of the biotechnology company’s stock worth $1,320,000 after acquiring an additional 25,627 shares during the period. Finally, HBK Sorce Advisory LLC acquired a new stake in Adaptimmune Therapeutics during the third quarter worth about $32,000.

Analysts Set New Price Targets

A number of equities analysts have commented on ADAP shares. EF Hutton Acquisition Co. I started coverage on shares of Adaptimmune Therapeutics in a report on Thursday, January 5th. They issued a “buy” rating and a $10.00 price objective on the stock. Guggenheim upgraded shares of Adaptimmune Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, January 3rd. Mizuho upgraded shares of Adaptimmune Therapeutics from a “neutral” rating to a “buy” rating and set a $9.00 price objective on the stock in a report on Wednesday, November 9th. Wells Fargo & Company boosted their price objective on shares of Adaptimmune Therapeutics from $1.50 to $3.00 and gave the stock an “equal weight” rating in a report on Monday, November 14th. Finally, StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Adaptimmune Therapeutics Stock Performance

Shares of Adaptimmune Therapeutics stock opened at $1.71 on Monday. The firm has a market cap of $280.15 million, a PE ratio of -1.57 and a beta of 2.23. The firm’s 50-day simple moving average is $1.81 and its 200-day simple moving average is $1.74. Adaptimmune Therapeutics has a 1 year low of $1.01 and a 1 year high of $3.32.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) last issued its earnings results on Tuesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $7.01 million for the quarter, compared to analyst estimates of $4.40 million. Adaptimmune Therapeutics had a negative net margin of 998.26% and a negative return on equity of 112.16%. On average, equities analysts predict that Adaptimmune Therapeutics will post -1.09 earnings per share for the current year.

Adaptimmune Therapeutics Company Profile

(Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Read More

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.